Alexandria Real Estate Equities-backed exosome therapy developer Codiak Biosciences has filed to raise up to $100m having pulled back from an earlier offering last year.

Codiak Biosciences, a US-based exosome drug developer that counts life science real estate investment trust Alexandria Real Estate Equities as an investor, refiled for an initial public offering on Wednesday. The company had previously filed to raise up to $86.3m in an offering on the Nasdaq Global Select Market in April 2019 before withdrawing its…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.